
United States · Insurance startup
Kalepa is an insurtech company founded in 2018, based in New York City.
Funding reportedLast round: Series A
Kalepa is an insurtech company founded in 2018, based in New York City.
It specializes in AI-powered decision support software for commercial and specialty insurance underwriters. The company aims to enhance the underwriting process by providing data-driven insights and active learning, helping insurers accurately price risk and identify profitable opportunities. Kalepa's flagship product, Copilot, serves as a decision-support engine for underwriters. It analyzes vast amounts of data to automate tasks such as loss run processing, risk sorting, and hazard analysis. The platform continuously improves its AI models based on user feedback, offering actionable insights and recommendations to optimize underwriting performance. Kalepa operates on a Software-as-a-Service (SaaS) model, providing subscription access to its platform. The company serves various sectors within the commercial and specialty insurance market, including property and casualty insurers, specialty carriers, and reinsurers. Kalepa has been recognized as an InsurTech100 company for four consecutive years and has secured significant funding from notable investors.
Funding, as reported
From Kalepa's own website: 2 on the team.
What they build
Known for
guideline adherencerisk exposure identificationenterprisesinformation technology & servicesinsurancerisk data sourcesai model transparencyfinancial servicesfinanceai underwritingunderwriting platformriskunderwriting guidelinesenterprise softwarerisk exposure detectionrisk decision support
Built with from their website
SailPointAzure Data Lake AnalyticsWeaviateMicrosoft Azure MonitorServiceNow Configuration Management DatabaseGitHub ActionsaccessiBeAzure DevopsPlanview LeanKitServiceNow
Azure DDoS ProtectionJira Service ManagementIBM SMP/EIoTParallels Mac Management for Microsoft SCCMAzure VPN GatewayDockerAdobe
Add your raise, your deck and your story, and put Kalepa in front of investors. Or tell us what we have wrong.